SARS-CoV-2 molecular testing in Greek hospital paediatric departments: a nationwide study. (24th February 2021)

• Record Type: Journal Article
• Authors: Michos, Athanasios; Savvidou, Parthena; Syridou, Garyfallia; Eleftheriou, Eirini; Iosifidis, Elias; Grivea, Ioanna; Spoulou, Vana; Galanakis, Emmanouil; Syrogiannopoulos, George; Tsolia, Maria; Roilides, Emmanuel; Papaevangelou, Vassiliki
• Is Part Of: Epidemiology and infection. Volume 149(2021)
• Publication Date: 2021-02-24
• Subjects: Children, -- COVID-19, -- diagnosis, -- epidemiology, -- SARS-CoV-2, -- testing; Communicable diseases -- Periodicals; Epidemiology -- Periodicals; 614.4
• DOI: 10.1017/S0950268821000455
• Languages: English
• ISSNs: 0950-2688

Abstract

Abstract: As most children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present with mild symptoms or they are asymptomatic, the optimal strategy for molecular testing it is not well defined. The aim of the study was to determine the extent and aetiology of molecular testing for SARS-CoV-2 in Greek paediatric departments during the first phase of the pandemic and identify possible differences in incidence, depending on the age group and geographical area. We conducted a nationwide study of molecular testing for SARS-CoV-2 of children in paediatric departments between March and June 2020. A total of 65 paediatric departments participated in the study, representing 4901 children who were tested for SARS-CoV-2 and 90 (1.8%) were positive. Most paediatric cases were associated with topical outbreaks. Adolescents 11–16 years had the highest positivity rate (3.6%) followed by children 6–10 years (1.9%). However, since the testing rate significantly differed between age groups, the modified incidence of SARS-CoV-2 infection per age group was highest in infants <1 year (19.25/10 5 population). Most children tested presented with fever (70.9%), respiratory (50.1%) or gastrointestinal symptoms (28.1%). Significant differences were detected between public and private hospitals regarding the positivity rate (2.34% vs. 0.39%, P -value <0.001). Significant variation in SARS-CoV-2 molecular testing positivity rate and incidence between age groups indicate discrepancies in risk factors among different age groups that shall be considered when ordering molecular testing.